ABSTRACT Enzymatic estimates of myocardial infarct size based on plasma levels of MB creatine kinase (MB-CK) were 
SERIAL CHANGES in plasma creatine kinase (CK) have been widely used to estimate myocardial infarct size in experimental animals and man. The method was developed in the early 1970s' 2 and has been used subsequently in both experimental and clinical studies. Although enzymatic estimates correlate well with other clinical parameters reflecting infarct size,3-6 few direct comparisons with postmortem anatomic measurements have been made.7' 8 Thus, the accuracy and limitations of the method have still not been completely established. 9 The present study compares infarct size estimated from plasma MB-CK levels with anatomic infarct size DIAGNOSTIC METHODS-MYOCARDIAL INFARCTION years of age, and (4) could be randomly assigned to a study group and treated within 18 hr after the onset of pain. Patients were excluded from the study for a variety of reasons that have been described previously. 10 Patients who were enrolled in the study were randomly assigned to either a control group or to one of two treatment groups, one receiving propranolol and the other hyaluronidase. One of the primary purposes of the study was to assess whether therapy limited infarct size, as determined from enzymatic estimates based on serial changes in plasma MB-CK. The details of the patient randomization procedure and treatment have been O sented elsewhere. 0 Collection of plasma samples for CK analysis. Collection of serial blood samples for measurement of levels of CK and the MB-CK isoenzyme was initiated before randomization and continued for the length of hospital stay. Blood samples were collected hourly for the initial 4 hr, at 2 hr intervals for the next 4 hr, and at 4 hr intervals for the subsequent 72 hr, followed by sampling every 8 hr for the next 48 hr and every 12 hr for the remaining hospital stay. Samples were labeled with the patient's MILIS identification number, centrifuged, stored, and shipped as previously outlined.'0 CK analysis and estimation of infarct size. For diagnosis of myocardial infarction and estimation of infarct size, total plasma CK activity was assessed by the Rosalki method" and that of MB-CK was assessed by the glass bead-batch adsorption technique12 and by radioimmunoassay'3; however, all results presented herein are based on the former method. The coefficient of variation for repetitive analysis of the total plasma CK assay was 4.2%, and that for MB-CK by the glass bead-batch adsorption method was 4.8%. In addition to internal repeated analyses to ensure reproducibility, the MILIS program included an ongoing audit of quality control of clinical and laboratory data. For the CK laboratory, samples were collected in duplicate from a random sample of patients and shipped from the clinical center, 1 to 3 months apart. Laboratory analyses of these samples were performed without knowledge that they were duplicates.
The diagnosis of myocardial infarction was confirmed if the plasma MB-CK level was elevated according to one or more of the following criteria: (1) values greater than or equal to 13 IU/ liter in at least two or more sequential plasma samples obtained within a 12 hr period, (2) a value greater than or equal to 13 IU/ liter obtained in one plasma sample, if this represented a threefold increase above the previous values, (3) a single value greater than or equal to 13 IU/liter if it was the only sample analyzed.
Infarct size was estimated from changes in plasma MB-CK activity, as previously outlined. 14 If the initial value for plasma MB-CK activity was elevated above normal, infarct size was calculated according to the recently described modification of the MB-CK method'5 (see Appendix for formulas). In these calculations, enzymatic estimates of infarct size were expressed in gram-equivalents based on an assumed proportionality between grams of infarct and total amounts of enzyme released.
Enzymatic estimation of infarct size could not be performed in patients who presented to the hospital after peak plasma MB-CK activity or in whom the samples were of poor quality, for example, because of hemolysis, which precluded accurate estimates of plasma total CK or MB-CK levels (table 1). Of 49 patients that underwent postmortem examination, plasma samples were sufficient for enzymatic estimation of infarct size in 37. In the other 12 patients enzymatic estimates were not made because of insufficient number or poor quality of specimens. However, peak plasma total CK and MB-CK levels could be obtained in one of these patients.
Anatomic methods. Permission for autopsy was obtained from the families of 49 patients who died after being enrolled in the MILIS study. These deaths occurred at various times from 14 hr to more than 6 months after enrollment. The hearts were obtained during the autopsy and sent by the local cardiovascular pathologist to the core pathology laboratory at Duke University. On receipt, each heart was x-rayed and weighed. After formalin fixation, the coronary arteries were examined by cross sectioning at 2 mm intervals, and the ventricles were cross sectioned into five or more slices approximately 1 cm thick. 16 The basal surface of each heart slice was photographed and 8 inch x 10 inch enlargements of these photographs were made. For histologic analysis, eight to 10 sections were taken to include the entire apical surface of each slice. These histologic slides were compared with the photograph of the adjacent basal surface of each subsequent slice. The outline of each infarct was drawn on the photographs based on the combined gross and microscopic appearances. For old infarcts, a correction was made for apparent loss of infarct mass due to removal of necrotic muscle, as evidenced by wall thinning. In hearts with patchy infarcts, the amount of involvement of a given region was estimated to the nearest 25%. An X-Y digitizer was used to planimeter the endocardial and epicardial borders of the left and right ventricles and the margins of all infarcts present on each photograph. The total volume of each infarct was then calculated by computer'6 and expresssed in cubic centimeters (1 cc -1.05 g).
Reasons for inclusion, exclusion, and subgrouping of patients based on anatomic factors (table 2) Inclusions. Anatomic estimates of infarct size are reported for are more than 6 months old. In nine hearts, older infarcts were present in more than one vascular distribution. The ages of these infarcts could not be established (other than '6 mo), and either the number of separate episodes of infarction was unknown, the boundaries of adjacent infarcts were uncertain, or the ECG localization of the qualifying infarct was questionable. Thus, these nine hearts were excluded from analysis. Three additional hearts were excluded because the qualifying infarct, although identifiable, could not be accurately sized: two infarcts were less than 24 hr old and infarct boundaries were not well defined; the third heart had an old infarct with a massive aneurysm that precluded accurate sizing.
The 37 hearts included in this study were subgrouped according to whether the infarct was relatively recent (1 to 16 days) or older (' 17 days) because fewer assumptions are required to estimate the size of younger infarets. In recent infarcts necrotic muscle is still present, but in older infarcts the necrotic muscle has been replaced by scarring. Estimation of scar size is straightforward but does not represent an accurate estimate of the size of the MILIS infarct before it is replaced by scar. It is known from studies in the dog that myocardial scars are con- densed as compared with the initial mass of necrotic muscle. '7 For this reason, when wall thinning was observed in the region of an old infarct, this thinning was considered to be the result of the loss of muscle mass and infarct size was corrected accordingly. Nevertheless, it is not clear how accurately such corrected scar size reflects the size of the original mass of necrotic muscle. Because of this uncertainty, anatomic estimates of original infarct size should be more accurate for recent infarcts than for older ones. Analysis of precision of anatomic estimates of infarct size. The anatomic estimate of the size of the MILIS infarct in each heart has been made by one of four investigators in the core pathology laboratory. To evaluate the precision of the anatomic estimates, 12 qualifying MILIS infarcts were independently sized by two or more investigators in the core laboratory. In this duplicate analysis, a separate set of photographs of the gross ventricular slices and the corresponding histologic sections were given to each investigator, who independently estimated infarct boundaries, degree of infarct patchiness, and extent of wall thinning. Tracings were made of the ventricular slices and infarct boundaries independently by each investigator, and these were entered into the computer for calculations of infarct size as described previously. In addition, infarcts were sized in three hearts by Dr. L. M. Buja errors due to less reliable anatomic sizing of old infarcts or to extrapolation of incomplete CK curves were not a major cause of discrepancy between the CK and anatomic estimates of infarct size.
Comparison of the slope of the regression line vs the line of unity in figure 1 indicates that, on the average, an increase of 1 geq of infarcted tissue estimated by CK does represent an approximate increase of 1 g of tissue obtained at autopsy. However, on the average, MB-CK estimates of infarct size were 8 g less than anatomic estimates. In contrast, estimates of infarct size based on curves of total CK were more often slightly larger than anatomic estimates ( figure 2) .
Peak values for MB-CK and total CK were available in 11 patients who had insufficient or poor-quality blood samples that precluded calculation of a CK estimate of infarct size. In the 36 patients for whom both anatomic and peak CK measurements were available, the correlation coefficients were .76 and .79 for anatomic infarct size vs peak MB-CK and peak total CK estimates, respectively (table 4) .
Although a strong positive correlation was observed between enzymatic and anatomic estimates of infarct size, there was considerable scatter of individual data points ( figure 1 and 2 ). This scatter could be related to imprecision either in the methods used or the assumptions required to calculate the anatomic and enzymatic estimates of infarct size or to a combination of such factors.
Interobserver variability in estimating anatomic infarct size was assessed in 15 of the MILIS hearts selected at random (table 5, figure 5 ). In these hearts infarct size was calculated by two or more observers using the same photographs and histologic sections but independently determining infarct boundaries and degree of patchiness and independently entering the data into the computer. The mean absolute difference was 6.5 cc or 19% of the original anatomic estimate that had been reported to the data coordinating center. The correlation between estimates was .96. To assess laboratory reproducibility and the effect of sample collection techniques, labeling, and the effect of storage and transport on CK activity, duplicate blood samples were obtained from 62 patients selected at random. The two sample sets were sent to the CK core laboratory several weeks apart; the personnel in (25) .84 (14) .79 (11) .88 (15) IS, total .86 (25) .86 (14) .89 (11) .83 (15) Peak, MB .76 (36) .72 (24) .79 (12) .83 (15) Peak, total .79 (36) .78 (24) .86 (12) .76 (15) Values are Spearman correlation coefficients for the indicated enzymatic variable vs anatomic infarct size for the entire group of infarcts and for selected subgroups. Number of infarcts available for each comparison is indicated in parenthesis. For these analyses, anatomic infarct size includes both right and left ventricular components of the infarcts. The analyses include those patients with no infarction (infarct size = 0) by CK or anatomic evaluation.
IS, MB = infarct size estimated from MB-CK; IS total = infarct size estimated from total CK. the core laboratory were not aware that the samples in the second set were duplicates. The variation in MB-CK infarct size within the 62 duplicate patient sets was 62 (geq/mY)2, while the variation among the 62 patients was 785 (geq/m2). The reproducibility coefficient, defined as the ratio of the between-patient variation to the sum of the between-plus within-patient variation, was 93%. The large reproducibility coefficient indicates that the majority of the variation in the data was the result of differences among patients rather than differences between duplicate estimates of infarct size in the same patient.
The possibility that reperfusion of myocardial infarcts may have occurred in some patients was considered. Of 23 infarcts less than 16 days old (27 MILIS events minus two anatomic exclusions and two with no infarct), 15 were associated with complete occlusions of the corresponding coronary artery. Early reperfusion presumably did not occur in these patients. The other eight recent infarcts, three of which were circumferential nontransmural infarcts, were associated with one or more subtotal coronary occlusions at autopsy (table 3). In this subgroup of patients it is possible that initial ischemia was followed by reperfusion. In four of the eight hearts in which infarcts were measured anatomically, enzymatic estimates of infarct size were also obtained. Results in two of these four were above and two were below the regression line shown in figure 1 . An early time of peak plasma CK activity could also be a reflection of spontaneous reperfusion. In the present series, seven of eight patients in whom enzyme levels peaked relatively early had small infarcts (at the low end of the relationship shown in figure 1 peak total CK levels correlated almost as well with the anatomic estimation of infarct size as did the calculations of infarct size computed with the complete enzymatic curves (table 4) . Thus, in those patients in whom complete enzyme curves are not available, peak values of enzyme activity also may be useful indexes of relative infarct size. Previous studies have shown that peak CK best reflects total CK release when the upslope and downslope of the curve are rapid and the peak is sharp.'9 However, it should be noted that, as in the present study, peak levels of enzyme activity must be identified from blood samples drawn at frequent intervals. In clinical situations in which sampling is less frequent, identification of peak activity will be less accurate.
Factors influencing accuracy of anatomic estimates of infarct size. Potential sources of error in the anatomic estimation of infarct size include changes in the myocardium between the time of the MILIS infarct and subsequent death of the patient and errors in the anatomic measurements, per se. Ideally, the anatomic measurements of infarct size should reflect infarct size at the time of MILIS entry when enzymatic estimates are obtained. The assumption that this is true becomes more tenuous with increasing time between the onset of infarction and death of the patient. An infarct is not a static entity but initiates a sequence of inflammatory and reparative reactions that alter the apparent size as well as the character of the infarct. During the first few days, infarcts are edematous and may have variable amounts of acute inflammation and hemorrhage that increase their mass and cause overestimation of actual necrotic myocardium.'7 By 4 or 5 days, however, the acute inflammatory response begins to recede and the reparative process becomes dominant. Necrotic myocardium is removed by macrophages and is replaced by granulation tissue. During the next 3 to 6 months, collagen is gradually produced and eventually the infarct is converted to a dense scar. Such scars may occupy only a fraction of the mass originally occupied by infarcted myocardium. 17 At the same time, hypertrophy of surrounding viable myocardium occurs and, although it does not affect the calculated mass of the infarct, it does cause a progressive reduction in the apparent percentage of the heart involved by the infarct.
To compensate for the reparative process, an estimate has been made of loss of myocardial mass based on wall thinning in the region of the infarct compared with noninvolved areas of myocardium. Infarct sizes reported for infarcts older than 16 days are based on the Vol. 70, No. 5, November 1984 sum of the measured scar size and an estimate of myocardial loss based on wall thinning. Because there is no way of verifying the accuracy of these corrected estimates of infarct size, these anatomic estimates have greater potential for error than those made in hearts from patients who died soon after MILIS admission. For this reason, patients have been subgrouped according to length of time from MILIS event to death, with the expectation that anatomic estimates of infarct size might be most accurate in patients who died during the first 16 days (recent infarcts). Nevertheless, the correlation coefficients for the relationship between enzymatic and anatomic estimates of infarct size were similar for both recent and older infarcts, suggesting that the above corrections for older infarcts have been appropriate. When only recent infarcts were considered, the point scatter was similar to that observed for the entire group (figures 1 to 4).
Anatomic estimates of infarct size could be erroneously large if infarcts that occurred before or subsequent to the MILIS infarct were included in the anatomic estimate of infarct size. In the case of recent infarcts, the characteristic sequence of inflammatory and reparative changes make it possible to establish the approximate age of an infarct based on the histologic features observed.2>22 In 36 hearts no more than one discrete infarct was identified that had a histologic age consistent with the duration from onset of the MILIS event to death. Any earlier or later infarcts were readily separable by histologic character. On the other hand, once the healing process is complete, it becomes impossible to establish the age of a scar. In nine hearts, older infarcts were present in more than one vascular distribution and the number of separate episodes of infarction could not be established with certainty. These hearts have been excluded from analysis.
It also is possible that infarct extension could occur in the same vascular distribution as the initial MILIS event. Later infarct extension would not contribute to the initial enzymatic curve, but its effects might be anatomically inseparable from the initial event. In the series of patients reported, 11 had enzymatic evidence of infarct extension, but histologic evidence of extension was not observed in any of these hearts. (In the majority of these hearts, extension would not have been detectable whether or not it had occurred because of limitations in precise histologic dating of necrosis.) However, if infarct extension was a major event in these hearts, the anatomic size should have been erroneously larger than the enzymatic estimate. In fact, anatomic size exceeded enzymatic size in only four of the 11 cases of clinical extension.
A large number of the patients in this series developed cardiac arrest that required defibrillation at some time during their hospitalization. Most of these events were terminal or nearly terminal and would not have contributed either to the CK or anatomic estimates of infarct size. Six patients underwent successful cardiac resuscitation during the first 4 days of hospitalization but died 3 or more days later. If myocardial injury had been caused by resuscitative efforts in these patients, it should have been reflected in both the initial CK curve and the anatomic evaluation. A single patient (No. 32) required cardiac resuscitation on the eighth hospital day and died on the forty-eighth day. If resuscitation had caused additional cardiac injury, such injury might have been excluded from the CK estimate but included in the anatomic measurement of infarct size. However, CK analysis did not underestimate the anatomic infarct size in this patient.
The actual measurement of anatomic infarct size is also subject to error. Use of surfaces of five ventricular slices to represent infarction within an infinite number of potential slices is one source of error. Random errors may also be introduced at a number of technical steps, including identification of infarct boundaries on gross photographs, estimation of how solid or patchy the infarct is, correction for wall thinning in older infarcts, measurement of the thickness of each myocardial slice, and tracing ventricular and infarct boundaries with the ultrasonic digitizer. Systematic error may also be introduced by the assumptions incorporated into the computer-assisted calculation of infarct size.
To evaluate the extent of loss of precision caused by use of five rather than nine slices, results in seven non-MILIS human hearts that were studied previously were considered.'6 In these seven hearts, mean infarct size determined with nine slices was 18% of the left ventricle and the error introduced by use of only five slices averaged 0.6% (range 0 to 2.4%) of the left ventricle or 3.3% of the infarct size.
Interobserver variability is probably the major source of error in anatomic estimates of infarct size and was assessed in 15 of the MILIS hearts selected at random (table 5, figure 5 ). The statistical procedure used to determine the effect of this interobserver variability was to reestimate the correlations between anatomic infarct size and CK measurements of infarct size by assuming that anatomic interobserver variability was zero, i.e., that no measurement error existed for anatomic sizing. Factors influencing accuracy of enzymatic estimates of infarct size. The accuracy of infarct size estimated from changes in plasma CK depend in large part on the precision of the parameters required to make such calculations. The parameters were derived and verified in conscious animals, but parameters such as the plasma disappearance rate and the release ratio are difficult to verify directly in man. Thus, there is need for further studies in man comparing enzymatic and anatomic estimates of infarct size.
Estimates of infarct size based on total CK level were slightly larger than those based on plasma MB-CK. We hypothesize that the difference is due to MB-CK release from noncardiac sources. This is a reasonable but unproven assumption in patients with hypotension and decreased perfusion of skeletal muscle.
One particular concern raised from experimental studies in the dog regards the possible inaccuracy of the CK method for estimating large infarcts.8 23 24 In large infarcts with extensive microvascular damage, there may be less CK released into the blood from the CIRCULATION center of the infarct than there would be with a smaller infarct. The consequence would be enzymatic underestimation of infarct size. In the present study, despite a wide range of infarct sizes, enzymatic underestimation of large infarcts was not observed. Although enzymatic underestimation of infarct size has been observed with large infarcts in the dog, it has not been observed in man. Two studies7' 8 in addition to the present one have shown no underestimation of infarct size whether infarcts were small or large. In addition to the linear regression analysis we also analyzed the relationship between enzymatic and anatomic estimates by a quadratic function and still observed no tendency for under-and overestimation of infarct size with respect to small or large infarcts, despite a wide range of infarct sizes. There was a slight tendency for enzymatic estimates based on MB-CK to underestimate infarct size over the entire range of infarct sizes. The explanation for the difference between experimental animals and the patients in this study is not known. It is possible that collateral blood flow in patients with longstanding coronary atherosclerosis may have been greater, or microvascular damage less, than in dogs with sudden sustained coronary occlusions.
Another concern raised in studies of experimental infarction is that more rapid washout of CK might occur in patients with spontaneous reperfusion during the early phase of infarction.25 Whether early, spontaneous reperfusion did occur in some of the patients cannot be established with any degree of certainty from the anatomic studies, as discussed above.
Another concern is whether either of the possible treatments might have altered the relationship between enzymatic and anatomic estimates of infarct size (independent of any effect of treatment on infarct size per se). In the dog, propranolol given intravenously in a dose of 0.3 or 2 mg/kg increased the CK disappearance rate (kd).26 However, these doses are three and 20 times, respectively, the dose given to patients in the present study. We have not observed in man any change in kd derived from the downslope of the plasma CK time-activity curve between patients receiving propranolol and those in a control group. Also, in other experimental studies, therapeutic doses of a number of commonly used drugs have not altered the rate of clearance of CK 
